Avrobio
Cambridge
About Avrobio
Avrobio is a clinical stage company developing step-change cell and gene therapies targeting cancer and rare disease. The catalyst for creating Avrobio is to accelerate scientific breakthroughs related to the convergence of cell and gene therapies. The patient’s own cells can be effectively modified to deliver novel genes to cure serious debilitating disease. Avrobio was founded by industry leaders with unmatched scientific, business, and manufacturing expertise in the field of cell and gene therapy.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Delisted
- Employees: 101 – 250
- Estimated revenue: $10K – $50K
- Total funding: $85.0M
- Funding stage: M&A
- Last round: Series B (Feb 2018)
- Ticker: nasdaq:AVRO
- Website: avrobio.com
- Phone: (617) 914 8420
Industries & Categories
Biotechnology, Genetics, Health Care
Social Profiles
Canonical: https://fsome.com/organization/avrobio-126302 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.